Showing 2051-2060 of 3172 results for "".
Therapies in Practice: New Options for Ichthyosis Vulgaris
https://practicaldermatology.com/topics/general-topics/therapies-in-practice-new-options-for-ichthyosis-vulgaris/21933/Emerging data confirm that atopic dermatitis and ichthyosis share pathogenic traits, suggesting a role for barrier repair formulations in management.Dermatoscopy: Chaos and Clues
https://practicaldermatology.com/topics/general-topics/dermatoscopy-chaos-and-clues/21345/A decision algorithm for pigmented skin lesions.Which Probiotic for Which Disease? Part 2
https://practicaldermatology.com/topics/atopic-dermatitis/which-probiotic-for-which-disease-part-2/23596/The conclusion of this 2-part series reviews the research for probiotics in the management of AD, acne, and psoriasis.Tinea Incognito, the Great Imitator: Case Reports
https://practicaldermatology.com/youngmd-connect/resident-resource-center/tinea-incognito-the-great-imitator-case-reports/23925/What’s New in Topical Treatment for Actinic Keratosis?
https://practicaldermatology.com/topics/skin-cancer-photoprotection/whats-new-in-topical-treatment-for-actinic-keratosis/23483/An overview of the latest developments in treatment of these common precancerous lesions.Topical Treatment Options for Hyperhidrosis
https://practicaldermatology.com/youngmd-connect/resident-resource-center/topical-treatment-options-for-hyperhidrosis/23340/A review of topical therapies for primary focal hyperhidrosisTriple Threat
https://practicaldermatology.com/topics/general-topics/triple-threat/20629/In defense of the Aron Regimen for resistant atopic dermatitis.GLP-1 Receptor Agonists and the Aesthetic Patient: Considerations for the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1-receptor-agonists-and-the-aesthetic-patient/48900/The impact of glucagon-like peptide-1 agonists (GLP-1), such as semaglutide, tirzepatide and liraglutide, has transformed the healthcare industry and, in particular, aesthetic dermatology. The most common intended use of these medications, namely diabetes management and weight loss, can lead to a muTargeting the OX40 Pathway
https://practicaldermatology.com/issues/october-2025/targeting-the-ox40-pathway/39764/A Promising New Avenue in Atopic DermatitisComorbidities in Atopic Dermatitis
https://practicaldermatology.com/issues/october-2025/comorbidities-in-atopic-dermatitis/39756/In this article, as part of a series on comorbidities associated with immune-mediated skin diseases, we explore the spectrum of comorbidities linked to AD.